An Open Label, Randomized Control Proof of Concept Study to Compare the Effectiveness of Thiriloga Chendhuram (TC) with Annabedhi Chendhuram (ABC; Active Control) in the Treatment of Veluppu Noi (Iron Deficiency Anemia) in Women of Reproductive Age: A Prospective Double-Arm Clinical Trial Protocol Authors: Rajendra K. Arumugam, Gayathri Gunalan, Siva Annamalai, Archana Arivazhagan, Shyamala Rajkumar Published: 2025 ABSTRACT Background:Iron deficiency anemia (IDA) constitutes a worldwide health issue, particularly affecting women of reproductive age. Conventional treatments have limitations and side effects, prompting the exploration of alternative therapies. Siddha system of medicine offers potential remedies with minimal side effects. This trial aims to assess the safety and effectiveness of Thiriloga Chendhuram (TC), a herbometallic preparation from Siddha medicine, in the correction of IDA. The study also seeks to understand TC’s potential mechanisms of action through comprehensive hematological and biochemical investigations.Materials and Methods:This is an open-labeled randomized controlled proof-of-concept study with an active control. From SRRI, Puducherry OPD who meet the inclusion criteria are enrolled for this trial. The study site is Siddha Regional Research Institute, Puducherry. Trial participants are randomly assigned to two groups to receive either TC or Annabedhi Chendhuram (ABC-Active Control) at a 1:1 ratio. All the quantitative outcomes will be analyzed using SPSS software.Results:This study is expected to be completed in approximately 12 months, based on recruitment. The results of the study will be published in a peer-reviewed journal.Conclusion:This proof-of-concept study addresses the challenges of IDA in women of reproductive age, emphasizing the potential role of Siddha medicine and offering alternatives for managing IDA. This trial also assesses the reticulocyte hemoglobin content (CHr) and percentage of hypochromic cells (% hypo), which offer enhanced sensitivity, specificity, and reliability for diagnosing IDA. The findings will pave the way for future large-scale trials and also contribute to innovative approaches in addressing IDA. INTRODUCTION Anemia is described as reduction in the total count of red blood cells (RBCs) or hemoglobin concentration (Hb) and their oxygen-carrying capacity, which is inadequate to meet the physiological requirements of the body.[1] The World Health Organization (WHO) defines anemia as the level of hemoglobin is less than 11 g/dl for children and pregnant women, and less than 12 g/dl for nonpregnant women at sea level.[2] Anemia poses a serious global public health challenge, impacting 43% of individuals in developing nations and 9% in developed ones.[3] Anemia significantly impacts pediatric people, adolescent girls, women of reproductive age, as well as pregnant and postpartum women. As per the WHO, around 40%, 37%, and 30% of children aged 6 to 59 months, pregnant women, and women aged 15 to 49 worldwide are affected by anemia, respectively.[4] The 5th National Family Health Survey (NFHS-5), which was conducted from 2019 to 2021 in India, has reported that the prevalence of anemia in women of the reproductive age group (15-49) had risen by 57% nationally, from 53.1% as reported in NFHS-4 conducted between 2015 and 2016. In the state of Puducherry, a similar increase was noted, with a rise from 52.4% to 55.1%, respectively.[5] Anemia can result from various factors, including nutritional deficiencies (iron, folic acid, vitamin B12), genetic conditions (thalassemia, sickle cell disease), infections (malaria, tuberculosis, etc.), and socioeconomic factors. The severity of anemia varies by several factors such as age, gender, smoking and pregnancy leading to reduced oxygen-carrying capacity.[6] Iron deficiency anemia (IDA) is the most prevalent type of anemia globally.[37] Iron is a vital trace element, crucial for metabolic and biochemical processes. Prolonged deficit of iron can lead to IDA, a common micronutrient deficiency in developing nations. Iron deficiency typically progresses slowly and may not display noticeable symptoms until anemia becomes severe. According to WHO in 2020, IDA remains the primary global cause of anemia, resulting from insufficient iron for hemoglobin production, often due to low intake in diet or poor absorption.[6] Pregnant women and pediatric population are particularly vulnerable to anemia, due to the increased iron need during their developmental period.[6] IDA in pregnancy leads to various risks like intrauterine growth restriction, preterm birth, and low birth weight. Socioeconomic factors, especially in developing countries, play a significant role in these problems.[8] Iron deficiency anemia influences the developmental progress of a country in both economic and social aspects. It results in delayed cognitive and motor development among children and diminished work capacity in adults.[9] The Siddha system of Medicine (SSM) is an established branch of traditional Indian medicine in the southern part of India, offering healthcare that encompasses preventive, promotive, curative, rejuvenative, and rehabilitative measures through the application of a scientific and holistic approach.[10] Siddha medicine can complement existing approaches, offering more choices for healthcare providers and patients. Anemia can be clinically correlated with Veluppu Noi, mentioned in the Siddha classical texts Yuki vaittiya cintāmaṇi and Siddha Maruttuvam (Podhu). Veluppu Noi has been divided into five types: Vali, aḻal, aiyam, mukkuṟṟam, and toxic anemia. Apart from the above-mentioned types, there is another type called Mannun Veluppu Noi related to sand eating. Nīla pāṇṭu, alaca pāṇṭu, and Alimuka pāṇṭu are all subtypes of Pāṇṭu with symptoms of yellow or bluish discoloration of the body, excessive thirst, giddiness, mental depression, and diminished sexual potency in men.[1112] Siddha holds a rich heritage of remedies for addressing anemia. These diverse medicinal preparations draw upon plant-based, mineral, metallic, and animal-derived ingredients. Various Siddha formulations, including Cūraṇam, vaṭakam, maṇappāku, pāṇitam, ney, māttirai, ilakam, kaṟpam, centuram, and others, are of polyherbal and herbomineral or herbometallic origins, and these are at one’s disposal for the treatment of anemia. Due to their minimal or rare side effects, Siddha physicians widely employed some Siddha formulations for the effective treatment of anemia.[13] Thiriloga Chendhuram (TC) is one of the herbometallic preparations that was stated in Siddha Formulary of India (Part-II) indicated for the correction of anemia (Veluppu Noi) and congenital Hemoglobinopathies (Piṟavi vēluppu nōy). It is also indicated for various other types of diseases, such as acid peptic disease, vomiting, jaundice, dropsy, ascites, diarrhea, respiratory diseases, and poisonous bites. TC consists of the following substances as ingredients: purified iron powder (Ayappoṭi), purified iron slag/metallic oxide plus silicate of iron (Maṇṭūram), purified elemental iron (Urukku), bark juice of Syzigium cumini, and leaves of Ricinus communis.[14] The key ingredient of this formulation is iron, and it is specially indicated for various types of anemia, especially for congenital hemoglobinopathies. The previous preclinical studies show significant results of its hematinic activity and safety, also ensured through toxicity studies.[1516] Hence, TC is incorporated in this clinical trial as a test drug. Annabedhi Chendhuram (ABC) is one of the herbomineral formulations used in combating anemia. The effectiveness of this drug was established by a multicenter clinical trial conducted by CCRAS in 2009.[17] Furthermore, as part of the Tamil Nadu State Government’s health program, namely “Am’mā makappēṟu cañcīvi tiṭṭam,” a medicinal kit containing Mātuḷai maṇappāku and Annabedhi Chendhuram has been distributed to pregnant women since 2016, aiming to prevent anemia during pregnancy.[13] This Siddha medication has been incorporated in this clinical trial as a positive control because of its notable effectiveness in reducing anemia. Economically, food-based and targeted iron supplementation strategies proves cost-effective in addressing iron deficiency. Various allopathic iron formulations, like ferrous sulphate and ferrous fumarate, are available for treating anemia, but their long-term use can lead to alimentary tract related side effects. Thus, it is the need of the hour to explore alternative therapies to overcome these difficulties. Hence, this trial was aimed to evaluate the safety and effectiveness of Thiriloga Chendhuram, a herbometallic preparation from the SSM, in the correction of iron deficiency anemia and understanding its potential mechanisms of action through various hematological and biochemical analysis. This randomized controlled trial (RCT) holds significant importance of Thiriloga Chendhuram in combating iron deficiency anemia. It provides a scientific framework for validating the effectiveness of Thiriloga Chendhuram and makes it as an evidence-based medicine with patient safety. This trial contributes to treatment comparisons, knowledge dissemination, and healthcare policy influence, ultimately integrating Siddha medicine into the broader healthcare system to address iron deficiency anemia. The outcome of this trial can expand the range of treatment options available for addressing iron deficiency anemia, and it may lead to the inclusion of Siddha medicine in public health strategies for the treatment of IDA. The primary objective of this clinical trial encompasses the assessment of both the safety and effectiveness of the investigational drug, Thiriloga Chendhuram. Additionally, the study also aims to quantify the biochemical changes occurring in the blood and red blood cell (RBC) levels both before and after the treatment. In parallel, a secondary objective involves verifying the patient’s prognosis, even in the aftermath of the therapeutic intervention, and also in understanding its potential mechanisms of action through various hematological and biochemical analyses. MATERIALS AND METHODS The SPIRIT checklist is a set of guidelines designed to improve the quality and completeness of clinical trial protocols. The study follows the SPIRIT checklist for protocol development, as well as for its reporting.[18] Trial design This study is designed as a double-arm, open-label, and proof-of-concept study with an individually randomized controlled trial (RCT). Its primary aim is to evaluate and compare the effectiveness and safety of Thiriloga Chendhuram (TC) with Annabedhi Chendhuram (ABC; active control) in treating Veluppu Noi (iron deficiency anemia) in women of reproductive age. The assessment of interventions effectiveness will be based on the primary and secondary objectives outlined in the study. This proof-of-concept study is a crucial step in providing preliminary evidence for the potential effectiveness of TC in the correction of IDA, paving the way for further research and potential integration into clinical practice. Study setting and site All participants (women of reproductive age group) will be recruited from the Outpatient Department of the Siddha Regional Research Institute, Puducherry, for this proof-of-concept study. The recruitment period will begin in February 2024. Sample size A total of 46 eligible patients, meet the predefined Inclusion Criteria will be recruited in the study. Enrollment will be contingent on their voluntary provision of informed consent by signing the informed consent form. Trial patients will be randomly assigned to two groups, namely, Group A and Group B, in a 1:1 ratio. Each group will consist of 23 patients. Eligibility criteria The inclusion criteria of this clinical trial is as follows: Participants should be aged between 18 and 45 years; hemoglobin levels should be within the range of 6 to 10 gm/dl; presence of at least four of the following clinical findings: i) serum iron content below 50 µg/l, ii) serum ferritin below 30 µg/l, iii) hematocrit/PCV below 35%, iv) total iron-binding capacity (TIBC) above 450 µg/dl; v) mean corpuscular hemoglobin concentration (MCHC) level below 34 g/dl; vi) mean corpuscular volume (MCV) level below 80 fl; vii) peripheral blood smear indicating hypochromic and microcytic anemia. The patients who do not fulfil the following exclusion criteria will not be enrolled for this clinical study: 1) pregnant women and lactating mothers, 2) individuals with severe renal, hepatic, or cardiac diseases, 3) known cases of diabetes mellitus and hypertension, 4) other clinical conditions such as bleeding piles, hematemesis, melena, etc., which results in frequent blood loss, and 5) dimorphic anemia. Rational and overview of the intervention The economic consequences of iron deficiency and diverse intervention tactics to address it indicate that employing food-based methods and focused supplementation is a cost-efficient strategy. Many iron based formulations from the allopathic medicines are available for treating iron deficiency anemia, such as ferrous sulfate, ferrous fumarate, and ferric hydroxide polymaltose complex, among others. However, long-term use of these iron salts is related with various alimentary tract side effects like epigastric discomfort, nausea, and constipation. An alternative treatment strategy is needed to increases the dietary iron absorption rather than increasing dietary iron intake. Various substances, including surface acting agents, carbohydrates, and ascorbic acid, have been explored for this purpose, among which ascorbic acid is a good one. Despite the availability of numerous iron preparations for anemia correction, the need for better options persists globally. This trial aims to address this need by evaluating the safety and effectiveness of Thiriloga Chendhuram, a herbometallic preparation from the traditional Siddha medicine, used for treating iron deficiency anemia since ages. Scientific validation of its hematinic properties has not been conducted previously. Hence, the study focus to create scientific evidence for this time-tested traditional formulation through phase II randomized clinical trial via proof of concept principle. The study also intends to investigate the hematological and biochemical changes in blood and also in RBC to understand the potential mechanism of action of this trial drug. Study outcomes and measures The primary outcome is assessment of both the safety and effectiveness of the investigational drug, Thiriloga Chendhuram. Clinical evaluations will be conducted in every visit (Day 4, 18, 33, and 49). These assessments comprises of examinations that are based on the basic principles of the Siddha, including Uṭaliyal (body constitution), Uyir tātukkaḷ (three vital humors), Uṭal tātukkaḷ (seven bodily tissues), Eṉvakait tērvukaḷ (eight-fold examination of body), Porikal/pulaṉkaḷ (senses), and Kōcaṅkal (systemic examination).[17] Additionally, we will also measure the biochemical changes occurring in the blood (whole blood: Hb, CBC, PCV, and RBC indices; serum/plasma: serum iron, TIBC, peripheral blood smear, serum ferritin, serum transferrin, sTfR, serum erythropoietin, CRP, serum oxidative stress, serum/plasma antioxidants, methemoglobin, lipid profile, LFT, and RFT; and also in red blood cell (RBC) levels (RBC: Hb electrophoresis, biochemical profile, oxidative stress assessment, and antioxidants assay) both before and after the treatment. The secondary outcomes will be assessed through verifying the patient’s prognosis, even in the aftermath of the therapeutic intervention, and also in understanding its potential mechanisms of action through various hematological and biochemical analyses [Table 1]. Table 1Time point of the trialTime pointStudy periodEnrollmentAllocationTrial periodFollow-up 0th day15th day30th day45th day1st month3rd month6th monthEnrollment Eligibility screeningX Informed consentX Socioeconomic data collectionX RandomizationXXDeworming T. AlbendazoleXInterventions Annabedhi chendhuram (ABC)XX Thiriloga chendhuram (TC)XXAssessmentsLab Investigations Hematology (CBC)XX Anemia profile#XX Special investigations*XX Diabetic and lipid profile, RFT, and LFTXXX Urine investigationsXXX ECGXXXClinical outcome Physical examinationXX Examination as per the Siddha concept[19]XX Clinical data collectionXX#Serum Iron, TIBC, Peripheral blood smear, Serum ferritin, Serum Transferrin, sTfR, Serum erythropoietin. *Oxidative Stress Assessment−TBARS, Lipid Hydroperoxides, Conjugated dienes; Antioxidant status−Reduced Glutathione, SOD, Catalase; RBC Studies−TBARS, Lipid Hydroperoxides, Conjugated dienes, Reduced Glutathione, SOD, Catalase, Total Proteins, Total Carbohydrates, Total ATPases in RBC membrane; Hb Electrophoresis and Methemoglobin. @Examination as per Siddha concept − Udaliyal (Body constitution), Porigal/Pulangal, Kosangal (Systemic Examination), Ezhu Udalkattugal (seven bodily tissues), Envagai Thervugal (eight-fold examination) Time point of the trial #Serum Iron, TIBC, Peripheral blood smear, Serum ferritin, Serum Transferrin, sTfR, Serum erythropoietin. *Oxidative Stress Assessment−TBARS, Lipid Hydroperoxides, Conjugated dienes; Antioxidant status−Reduced Glutathione, SOD, Catalase; RBC Studies−TBARS, Lipid Hydroperoxides, Conjugated dienes, Reduced Glutathione, SOD, Catalase, Total Proteins, Total Carbohydrates, Total ATPases in RBC membrane; Hb Electrophoresis and Methemoglobin. @Examination as per Siddha concept − Udaliyal (Body constitution), Porigal/Pulangal, Kosangal (Systemic Examination), Ezhu Udalkattugal (seven bodily tissues), Envagai Thervugal (eight-fold examination) Randomization By using block randomization with the help of Microsoft Excel, the study participants will be assigned into two groups randomly at a 1:1 ratio. Group A, consisting of 23 patients, will receive Annabedhi Chendhuram (ABC; active control) – 200 mg with honey, BD, after meals for a duration of 45 days. Meanwhile, Group B, also comprising 23 patients, will be administered Thiriloga Chendhuram (TC) – 400 mg with honey, BD, after meals over the same 45-day period. Recruitment During the first visit, patients will undergo screening as per the Screening Proforma, which includes routine blood and urine tests. Patients who meet the inclusion criteria will be enrolled after obtaining their informed consent. Detailed patient history will be recorded as per CRF-A. Before drug administration, deworming using T. Albendazole 400 mg Stat will also be done. Stool and occult blood tests will be conducted on day zero and day 21 after deworming. The trial drug, Thiriloga Chendhuram, will be dispensed in 400 mg doses, and the control drug Annabedhi Chendhuram in 200 mg doses. Each drug will be packed in nonadhesive paper packets for its respective groups. Clinical assessments of trial subjects as per CRF-B for every 15-day review will be carried out during the treatment period. The blood investigations will be performed on day 0 and day 46. After 45 days of treatment, the administration of trial and control drugs will be discontinued, and a 6-month follow-up will be conducted to assess the potential recurrence of IDA. Blood tests will be conducted at each follow-up visit, occurring after the 1st, 3rd, and 6th months. The trial flow chart is depicted in Figure 1. Trial flowchart The study follows the TIDieR checklist to ensure transparency and reproducibility by outlining the key elements of the intervention, such as its content, delivery personnel, procedures, etc.[20] Data collection, management, and analysis Data collection methods The Principal Investigator and the clinical trial team will collect primary and secondary outcome data, including baseline data and hematology profiles, during participant visits. This data will be meticulously documented on assessment forms and endorsed by the investigator or an authorized delegate. Data management The clinical trial team will closely monitor the patients from baseline and also during specific time points, including days 15, 30, and 45. The study team also employs telephonic reminders for scheduled outpatient visits over a 6-month follow-up period. During outpatient visits, a detailed medical history will be obtained; complete physical examinations will be conducted, and both primary and secondary outcome data will be recorded on assessment forms, encompassing laboratory test results. Comprehensive records will be maintained for withdrawn participants. Furthermore, inquiries will be made regarding adverse events, study medication adherence, and the intake of concurrent medications, all of which will be thoroughly documented. Data analysis The research team will assess the quality of the data, including primary and secondary outcome-related data, laboratory test results, and baseline and follow-up data. This meticulous evaluation ensures the integrity of the clinical trial results. Statistical power and sample size calculations Taking a 20% drop-out rate into account, the total sample size needed to establish a significant difference in IDA between group A and group B is approximately 46 (comprising 23 patients in each group, specifically 18 patients plus an additional 5 patients for 20% drop-out). This will be well enough for this pilot study to encounter unanticipated problems that may arise. Statistical analysis The study team will consistently review and validate the medical records of participants, collecting and documenting pertinent data. All statistical assessments will be executed with SPSS 29.0 (or a newer version), employing one-sided hypothesis of superiority tests at a significance level of 0.05. Group comparisons will be accompanied by 95% confidence intervals and P values. Data summarization will default to presenting the mean ± standard deviation or median (minimum, maximum) unless otherwise specified, while countable data will be expressed as frequency (percentage). Risk mitigation plan/adverse events, and reaction reporting and safety assessment Adverse events and reactions will be documented during all time of the study. The principal investigator will promptly inform the IHEC about any adverse event that meets the following criteria: 1) associated with the investigational drugs or study treatment (s); 2) serious; and 3) unexpected. The Institutional Human Ethics Committee (IHEC) of Siddha Regional Research Institute, Puducherry, will oversee the monitoring of all potential AEs and ARs. If applicable adverse events arise, they will be reported to the IHEC and the Pharmacovigilance Cell of the Institute immediately and no later than 10 calendar days from the investigator’s receipt of the relevant information. Follow-up data regarding reported adverse events will be submitted to the IHEC when it becomes available. If the patients cannot tolerate the treatment during the trial, they have the option to withdraw at any time. Withdrawal criteria A patient may be withdrawn from the trial if they are unable to adhere to essential instructions or experience a severe, urgently treatable condition. Missing the prescribed drug regimen for three consecutive days will be considered noncompliance and may lead to the patient’s withdrawal from the study. DISCUSSION Iron deficiency anemia (IDA) is a more prevalent and concerning public health issue globally, particularly impacting women of reproductive age. This trial addresses the need for effective and safe interventions for IDA, acknowledging the limitations and side effects associated with existing allopathic iron formulations. The impact of IDA on women of reproductive age is profound and multifaceted. Iron deficiency during this period can lead to serious health consequences for both women and their offspring. Adverse outcomes include increased maternal morbidity, preterm births, low birth weight, and developmental issues in newborns. The rising prevalence of anemia, as highlighted in national family health surveys in India (NFHS), necessitates targeted interventions. Addressing IDA in women of reproductive age is crucial not only for their individual well-being but also for the broader societal impact, including maternal and child health outcomes. The recent systematic review and meta-analysis study about the preclinical and clinical studies of Siddha preparations advocate for anemia reveals that Siddha holds a rich heritage of remedies for addressing anemia with minimal or rare side effects, and this makes it an effective remedy for the treatment of anemia. These diverse medicinal preparations draw upon plant-based, mineral, metallic, and animal-derived ingredients.[913] Thiriloga Chendhuram (TC) is one of the hematinics from Siddha medicine for the correction of anemia. The rationale for choosing TC is to identify the effective management for anemia with minimal or no side effects. The scientific validation in terms of clinical trial for its hematinic property has not been conducted previously. Hence, this trial was aimed at to assess the safety and effectiveness of TC scientifically, contributing to evidence-based medicine and expanding the treatment options for IDA. Annabedhi Chendhuram (ABC) is a notable herbomineral remedy for anemia from Siddha medicine, it was validated by a multicentric clinical trial conducted by various Siddha Research Institutes under CCRAS in 2009.[17] With these established evidence based data, ABC was selected as positive control in this trial for its notable effectiveness in anemia correction. The comprehensive evaluation of various hematological and biochemical parameters in this trial provides a thorough understanding of the impact and potential mechanisms of TC in managing IDA. Hematological parameters, including hemoglobin levels and red blood cell indices, offer insights into the drug’s effectiveness in improving blood composition. Biochemical analyses, such as serum iron, ferritin, transferrin, TIBC, and sTfR, provide information on the drug’s influence on iron metabolism. Other parameters, including erythropoietin levels and oxidative stress markers, contribute to a holistic assessment of TC’s effects on erythropoiesis and also on the stability of RBC, respectively. This trial also aims to assess various new hematological markers for IDA to ensure a complete diagnosis. The new screening parameters for iron deficiency anemia, including reticulocyte hemoglobin content (CHr) and percentage of hypochromic cells (% hypo), provide enhanced sensitivity and specificity. These parameters offer a direct measure of functional iron for erythropoiesis, aiding in early detection of iron-deficient states. CHr reflects hemoglobinization in erythroid precursors over 3–4 days, while % hypo indicates iron status over 2-3 months. Notably, these parameters are unaffected by inflammatory responses, ensuring greater reliability compared to traditional assays.[21] Positive outcome from this trial holds promising future perspectives. If TC proves to be effective and safe, it could offer an alternative or complementary approach to existing treatments for IDA. Siddha medicine, deeply rooted in traditional Indian healthcare, could gain recognition and integration into broader healthcare systems. This trial provides scope for potential future studies exploring the role of Siddha medicine in addressing other health conditions and contributing to a more diverse and holistic healthcare landscape. CONCLUSION In conclusion, this trial serves as a crucial step in addressing the challenges posed by IDA in women, particularly in reproductive age. This proof-of-concept study is typically conducted to gather preliminary evidence supporting the feasibility, safety, and potential effectiveness of TC. The outcome of this study would lay the groundwork for larger, more comprehensive studies and potential integration into clinical practice. This pilot study can also be extrapolated to a multicentric trial with a large population to validate the safety and effectiveness of TC further. These kinds of clinical trials may also be translated to many other Siddha hematinics and other traditional formulations to explore their potential in the treatment of IDA. The focus on Siddha medicine and the comprehensive evaluation of parameters contribute to the trial’s potential impact on healthcare practices, policy-making, and the overall well-being of the population affected by IDA. The findings from this study could pave the way for innovative and culturally rooted approaches in managing iron deficiency anemia. Authors’ contributions All authors equally contributed to the manuscript preparation, including concept, design, and collection of the data, as well as the writing and revision of the article. Data availability statement The data of the current study are available from the corresponding author upon reasonable request. Conflicts of interest There are no conflicts of interest.